(-0.38%) 5 051.09 points
(-0.38%) 38 358 points
(-0.29%) 15 650 points
(-0.74%) $82.74
(-5.74%) $1.708
(-0.23%) $2 336.60
(-0.35%) $27.27
(-0.92%) $914.30
(0.16%) $0.936
(0.85%) $11.00
(0.12%) $0.804
(-0.98%) $92.28
Quarter results tomorrow
(bmo 2024-04-25)
Expected move: +/- 1.97%
-2.31% $ 46.59
@ $47.72
Ausgestellt: 23 Apr 2024 @ 20:50
Rendite: -2.36%
Vorheriges Signal: Apr 22 - 21:52
Vorheriges Signal:
Rendite: 1.44 %
Live Chart Being Loaded With Signals
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...
Stats | |
---|---|
Tagesvolumen | 705 883 |
Durchschnittsvolumen | 1.95M |
Marktkapitalisierung | 109.16B |
EPS | $0 ( 2024-02-01 ) |
Nächstes Ertragsdatum | ( $0.970 ) 2024-04-25 |
Last Dividend | $1.903 ( 2023-05-30 ) |
Next Dividend | $0 ( N/A ) |
P/E | 20.34 |
ATR14 | $0.975 (2.09%) |
Volumen Korrelation
Sanofi American Korrelation
10 Am meisten positiv korreliert | |
---|---|
PPH | 0.936 |
PWOD | 0.93 |
ACAHU | 0.925 |
WLFC | 0.914 |
NWFL | 0.914 |
EVOP | 0.913 |
ROST | 0.91 |
SGHT | 0.909 |
HZNP | 0.907 |
MGI | 0.907 |
10 Am meisten negativ korreliert | |
---|---|
LNSR | -0.936 |
MEDS | -0.922 |
VS | -0.919 |
LHDX | -0.915 |
STRC | -0.912 |
TIL | -0.911 |
QLGN | -0.91 |
ULBI | -0.91 |
PLMR | -0.909 |
SG | -0.909 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Sanofi American Korrelation - Währung/Rohstoff
Sanofi American Finanzdaten
Annual | 2023 |
Umsatz: | $43.07B |
Bruttogewinn: | $26.50B (61.52 %) |
EPS: | $4.31 |
Q4 | 2023 |
Umsatz: | $22.88B |
Bruttogewinn: | $14.68B (64.16 %) |
EPS: | $1.570 |
Q3 | 2023 |
Umsatz: | $12.70B |
Bruttogewinn: | $8.86B (69.75 %) |
EPS: | $2.01 |
Q2 | 2023 |
Umsatz: | $10.68B |
Bruttogewinn: | $7.41B (69.41 %) |
EPS: | $2.74 |
Financial Reports:
No articles found.
Sanofi American Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$3.28 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.462 | 2003-05-28 |
Last Dividend | $1.903 | 2023-05-30 |
Next Dividend | $0 | N/A |
Payout Date | 2023-06-23 | |
Next Payout Date | N/A | |
# dividends | 24 | -- |
Total Paid Out | $33.25 | -- |
Avg. Dividend % Per Year | 3.34% | -- |
Score | 4.99 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.30 | |
Div. Directional Score | 9.72 | -- |
Year | Amount | Yield |
---|---|---|
2003 | $0.462 | 1.49% |
2004 | $0.610 | 1.60% |
2005 | $0.799 | 2.01% |
2006 | $0.912 | 2.00% |
2007 | $1.145 | 2.48% |
2008 | $1.510 | 3.31% |
2009 | $1.419 | 4.34% |
2010 | $1.627 | 3.99% |
2011 | $1.822 | 5.55% |
2012 | $1.756 | 4.72% |
2013 | $1.862 | 3.89% |
2014 | $1.910 | 3.69% |
2015 | $1.618 | 3.55% |
2016 | $1.630 | 3.86% |
2017 | $1.577 | 3.84% |
2018 | $1.861 | 4.30% |
2019 | $1.739 | 4.06% |
2020 | $1.753 | 3.46% |
2021 | $1.906 | 3.91% |
2022 | $2.04 | 4.02% |
2023 | $3.28 | 6.69% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.139 | 1.500 | 7.23 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0627 | 1.200 | 7.91 | 9.49 | [0 - 0.3] |
returnOnEquityTTM | 0.108 | 1.500 | 9.92 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.579 | -1.000 | 4.21 | -4.21 | [0 - 1] |
currentRatioTTM | 1.267 | 0.800 | 8.66 | 6.93 | [1 - 3] |
quickRatioTTM | 0.827 | 0.800 | 9.84 | 7.87 | [0.8 - 2.5] |
cashRatioTTM | 0.360 | 1.500 | 9.11 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.132 | -1.500 | 7.80 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 9.29 | 1.000 | 7.67 | 7.67 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.20 | 2.00 | 7.27 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.60 | 2.00 | 7.20 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.225 | -1.500 | 9.10 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.678 | 1.000 | 2.03 | 2.03 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.260 | 1.000 | 6.80 | 6.80 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.615 | 1.000 | 7.69 | 7.69 | [0.2 - 2] |
assetTurnoverTTM | 0.452 | 0.800 | -0.322 | -0.258 | [0.5 - 2] |
Total Score | 12.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 14.12 | 1.000 | 8.67 | 0 | [1 - 100] |
returnOnEquityTTM | 0.108 | 2.50 | 9.95 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.60 | 2.00 | 8.13 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.98 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.20 | 2.00 | 7.27 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.579 | 1.500 | 4.21 | -4.21 | [0 - 1] |
pegRatioTTM | 0.645 | 1.500 | 9.03 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.180 | 1.000 | 8.01 | 0 | [0.1 - 0.5] |
Total Score | 7.30 |
Sanofi American
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.